Table 1.
Baseline characteristics.
| Patients (n = 13) | |
|---|---|
| Age, years | 62 [48–67] |
| Male | 12 (92.3%) |
| Charlson comorbidity index | 2.77 (1.1–4.4) |
| 4C Mortality score for COVID-19 | 10.4 (7.6–13.2) |
| Low risk | 1 (7.7%) |
| Intermediate risk | 4 (30.8%) |
| High risk | 5 (38.5%) |
| Very high risk | 3 (23.1%) |
| Onset of symptoms before admission, days | 5.8 (3.8–7.8) |
| Confirmed by COVID-19 antigen test | 3 (23.1%) |
| Confirmed by PCR | 10 (76.9%) |
| Comorbidities | |
| Hypertension | 9 (69.2%) |
| Diabetes | 6 (46.2%) |
| Gastroesophageal reflux disease | 1 (7.7%) |
| Acute myocardial infarction | 2 (15.4%) |
| Benign prostatic hyperplasia | 2 (15.4%) |
| Other | 6 (46.2%) |
| No comorbidities | 4 (30.8%) |
| Laboratory values on admission | |
| Leukocytes, ×103/μL | 8.9 (6.6–11.2) |
| Lymphocytes, ×103/μL | 0.7 [0.58–1.04] |
| Granulocytes, ×103/μL | 7.4 (5.3–9.6) |
| Granulocyte/lymphocyte ratio | 10.0 (6.9–13.1)* |
| C-reactive protein, mg/L | 203 (116–290)* |
| Glutamic oxaloacetic transaminase, U/L | 96 [42–113]* |
| Glutamate pyruvate transaminase, U/L | 75 (40–109)* |
| Gamma-glutamyl transferase, U/L | 131.1 (66.3–195.9)* |
| Alkaline phosphatase, U/L | 100.1 (68.3–131.9) |
| Lactate dehydrogenase, U/L | 1,164.8 (780.9–1,548.8)* |
| Blood urea nitrogen, mmol/L | 6.4 [4.8–13.3] |
| Creatine kinase, U/L | 160 [126–489]* |
| Initial antiviral therapy | 11 (84.6%) |
| Oseltamivir | 4 (30.8%) |
| Favipiravir | 6 (46.2%) |
| Lopinavir | 1 (7.7%) |
| Adjunctive therapy | |
| Dexamethasone | 2 (15.4%) |
| Hydrocortisone | 4 (30.8%) |
| Methyl-prednisolone | 4 (30.8%) |
| Tocilizumab | 4 (30.8%) |
| Anti-COVID-19 convalescent plasma | 5 (38.5%) |
Data are presented as mean (95% CI), median [IQR], or n (%), unless otherwise specified. PCR, polymerase chain reaction. U/L, unit/litre; ICU, intensive care unit.
*
represents elevated values.